Vivoryon Therapeutics N.v. · EURONEXT:VVY
Vivoryon Therapeutics — Investor Presentation (August 2026)
25 slides from Vivoryon Therapeutics's investor presentation, August 2026
Slide 1: Transforming the Treatment of Kidney Disease
Transforming the Treatment of Kidney Disease Consistent eGFR Improvement Signal in Two Independent Phase 2 Studies Supports Proposed DKD Development Path Vivoryon Therapeutics N.V. August 2026
Slide 2: Important notice and disclaimer
Important notice and disclaimer This document has been prepared by Vivoryon Therapeutics N.V. (the “Company” or “We”) strictly only for discussion purposes. This document does not constitute or form part of any offer or invitation to sell or issue, any offer or inducement or invitation or commitment
Slide 3: Developing new therapies that aim to preserve kidney function
Developing new therapies that aim to preserve kidney function and prevent progression to kidney failure 3
Slide 4: Investment Summary
Investment Summary Strong clinical evidence base Defined pathway to value creation First in class QPCT/L inhibitor varoglutamstat: Funding needed for Phase 2 start: • Statistically significant eGFR improvement vs. placebo in • €15M to interim value inflection point; €30M total two independent Phase
Slide 5: Developing new therapies with the aim of preserving kidney function
Developing new therapies with the aim of preserving kidney function and preventing progression to kidney failure Significant unmet need in Compelling data with lead Attractive opportunity with kidney disease program varoglutamstat defined value-creation steps Patients urgently need First oral agent
Slide 6: Varoglutamstat: Phase 2 data showed stabilization / improvement in kidney function
Varoglutamstat: Phase 2 data showed stabilization / improvement in kidney function in elderly adults supporting strategy to develop in DKD Clear strategy to develop varoglutamstat in DKD Evidence-based pivot to DKD ◆ Clearly defined Phase 2b trial for varoglutamstat in stage 3b/4 DKD (subject to fin
Slide 7: Diabetic kidney disease
Diabetic kidney disease Diabetes is a leading cause of chronic kidney disease Diabetes can lead to High risk of kidney failure in Dialysis and/or transplant structural and functional advanced disease (stage 3b/4) needed to replace function if damage of the kidneys kidney’s fail Current standard of c
Slide 8: Significant unmet need for new products that stabilize or improve kidney function
Significant unmet need for new products that stabilize or improve kidney function Current standard of care (SGLT2i, GLP-1RA) delays disease progression but leaves significant room for improvement in kidney and cardiovascular outcomes Typical changes in eGFR following introduction and Reduction in ma
Slide 9: Targeting inflammation and fibrosis offers a complementary approach to existing therapies
Targeting inflammation and fibrosis offers a complementary approach to existing therapies by tackling DKD at its roots Varoglutamstat: QPCT/L inhibitor Inflammation/ Inflammation/ Complementary approach Fibrosis Fibrosis Inhibition Inhibition of pro-inflammatory targeting inflammation/fibrosis; of p
Slide 10: Varoglutamstat reduces pro-inflammatory signaling by destabilizing key inflammatory molecules
Varoglutamstat reduces pro-inflammatory signaling by destabilizing key inflammatory molecules Varoglutamstat targets pro-inflammatory and pro-fibrotic pathways in kidney disease ACTIVED / SILENCED INFLAMMATORY Inflammatory pyroglutamated- protein version (pE) Impaired Varoglutamstat kidney treated Q
Slide 11: Varoglutamstat in kidney disease: counteracting loss of kidney function at multiple levels
Varoglutamstat in kidney disease: counteracting loss of kidney function at multiple levels Varoglutamstat Varoglutamstat Varoglutamstat HYPERTENSION (Pro-) Collagens I Chemokines Activation of mechanical stress and III, fibronectin e.g. CCL2, CCL7, CX3CL1 HIF pathways Inflammatory Adaptive cellular
Slide 12: Two independent randomized double-blind placebo-controlled Phase 2 studies
Vivoryon has evaluated varoglutamstat’s effect on kidney function in two independent randomized double-blind placebo-controlled Phase 2 studies VIVIAD Phase 2b (Europe) Parameter VIVIAD (Europe) VIVA-MIND (U.S.) Participants selection Mild AD, mean age 68 yrs Mild AD, mean age 72 yrs No. of particip
Slide 13: Beneficial kidney function effect consistently observed in VIVIAD and VIVA-MIND
Beneficial kidney function effect consistently observed in VIVIAD and VIVA-MIND Two independent studies confirm statistically significant and clinically meaningful improvement in eGFR LSmean difference of eGFR between varoglutamstat 600 mg BID and placebo (all participants, all visits with eGFR asse
Slide 14: Compelling beneficial effect on kidney function compared to placebo
Compelling beneficial effect on kidney function in study participants treated with varoglutamstat compared to placebo Change in eGFR over time; pooled data from VIVIAD and VIVA-MIND (MMRM); All participants; 600 mg BID varoglutamstat Varoglutamstat Clear and consistent separation of curves after 24
Slide 15: Meta-analysis confirms a robust treatment effect and larger effect size in diabetes
VIVIAD and VIVA-MIND: Meta-analysis confirms a robust treatment effect and a larger effect size in patients with diabetes versus without diabetes Difference of change from baseline between varoglutamstat (v) and placebo (p) of eGFR (MDRD) Up-titration ∆ = 1.8 mL/min/1.73m2 ∆ = 1.5 mL/min/1.73m2 p=0.
Slide 16: Strong improvement of eGFR in patients with lower baseline eGFR and diabetes
Varoglutamstat showed consistent and strong improvement of eGFR in patients with lower baseline eGFR values and diabetes Participants with diabetes & reduced kidney function (baseline eGFR levels in lower percentiles within the diabetes subgroup*; Treatment effect (annualized rate of change in eGFR
Slide 17: Varoglutamstat was well tolerated in VIVIAD and VIVA-MIND
Varoglutamstat was well tolerated in VIVIAD and VIVA-MIND Pooled safety analysis; all participants randomized to 600 mg varoglutamstat BID and placebo 90 80 Extensive safety package (# / duration) 70 Pharmacology / Phase 1 % of participants with an event 60 Phase 1 study: large trial with 205 partic
Slide 18: Varoglutamstat has potential to significantly improve patient outcomes
Varoglutamstat has potential to significantly improve patient outcomes by preserving kidney function Current SoC Varoglutamstat Shown to improve kidney function • Data from 2 independent Phase 2 studies • Prominent effect in participants with diabetes Kidney function Stabilizes or continues to decli
Slide 19: Well-positioned to address people with advanced disease
Varoglutamstat well-positioned to address people with advanced disease where treatment options are limited High unmet need in • Patients with DKD stage 3b/4 have high risk of progression to end-stage kidney disease and dialysis advanced DKD creates • Varoglutamstat aims to stabilize kidney function
Slide 20: Study design to generate robust clinical evidence in kidney disease
Study design to generate robust clinical evidence in patients with kidney disease and unlock asset value Double-blind placebo-controlled Phase 2b study in stage 3b/4 DKD on top of standard of care1 eGFR and urine sampling (every 6 weeks) All patients switch to once daily Randomization 600 mg active
Slide 21: Varoglutamstat has potential to drive significant value creation
Varoglutamstat has potential to drive significant value creation Large unmet need: Urgent need for therapies that stabilize or improve kidney function to prevent progression to kidney failure Compelling data: First oral product to show improvement in kidney function; observed Complementary new MoA w
Slide 22: Clear roadmap towards value creation
Clear roadmap towards value creation ~15mths post ~24mths post Today Key next step Outlook study start1 study start1 Funding for Start Phase 2 Interim Primary Phase 3/ study in DKD readout readout partnering Required to start First data in Comprehensive Advance to Study execution Phase 2 in DKD stag
Slide 23: Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Halle (Saale) Weinbergweg 22 06120 Halle (Saale), Germany Munich Franz-Josef-Delonge-Str. 5 81249 München, Germany IR@vivoryon.com www.vivoryon.com
Slide 24: Appendix
Appendix
Slide 25: Broad potential for QPCT/L inhibitors: Multiple avenues to value generation
Broad potential for QPCT/L inhibitors: Multiple avenues to value generation Therapeutic applications for QPCT/L inhibitors range across many immune-mediated diseases characterized by inflammation and fibrosis, providing additional development and partnership opportunities Primary focus Near-term opp
Vivoryon Therapeutics — Investor Presentation (August 2026) on 6ix